A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2012
At a glance
- Drugs AFP 464; Fulvestrant
- Indications Breast cancer
- Focus Therapeutic Use
- 06 Jan 2012 Actual patient number is 7 according to ClinicalTrials.gov.
- 26 May 2011 Status changed from not yet recruiting to recruiting.
- 15 Nov 2010 New trial record